Benzinga | Aug 26, 2021 07:59AM EDT

Morgan Stanley Initiates Coverage On IGM Biosciences with Overweight Rating, Announces Price Target of $100

Morgan Stanley analyst Michael Ulz initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Overweight rating and announces Price Target of $100.